Sam, R-I " risk" is reducing significantly, not just as interim takes longer, but as Suntrust suggests, AMRN passed an inflection point and bias is now higher PT as we approach interim with greater confidence of efficacy from a multitude of positive effects (Cherry + other pleiotropic effects ) that improve not ONLY CVD - but overall health.
Lastly, another benefit of a full trial run is showing reduction in hard mace (vs. angina ) and the reduction in all cause mortality.
We've got a winner in EPA gents...
News 
Market Data 
Discover 
